• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    12/19/23 8:07:32 AM ET
    $AIMD
    $ARQT
    $BMRA
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • Biomerica (NASDAQ:BMRA) shares rose 54.5% to $1.53 during Tuesday's pre-market session. The market value of their outstanding shares is at $25.7 million.
    • Cingulate (NASDAQ:CING) stock increased by 33.33% to $2.84. The company's market cap stands at $2.6 million.
    • Arcutis Biotherapeutics (NASDAQ:ARQT) stock increased by 31.14% to $3.2. The market value of their outstanding shares is at $302.0 million.
    • Panbela Therapeutics (NASDAQ:PBLA) shares increased by 30.54% to $0.6. The market value of their outstanding shares is at $3.0 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) shares rose 30.08% to $0.44. The company's market cap stands at $37.5 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 29.89% to $0.06. The company's market cap stands at $14.2 million.

    Losers

    • Minerva Surgical (NASDAQ:UTRS) stock decreased by 52.5% to $1.34 during Tuesday's pre-market session. The company's market cap stands at $11.8 million.
    • Checkpoint Therapeutics (NASDAQ:CKPT) shares declined by 50.31% to $1.65. The company's market cap stands at $38.8 million.
    • Structure Therapeutics (NASDAQ:GPCR) stock declined by 45.24% to $32.4. The market value of their outstanding shares is at $1.5 billion.
    • Lantheus Holdings (NASDAQ:LNTH) shares declined by 18.8% to $61.75. The market value of their outstanding shares is at $4.2 billion.
    • Ainos (NASDAQ:AIMD) shares fell 18.08% to $2.72. The company's market cap stands at $12.7 million.
    • Blue Water Biotech (NASDAQ:BWV) shares decreased by 16.08% to $0.2. The market value of their outstanding shares is at $3.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $ARQT
    $BMRA
    $BWV

    CompanyDatePrice TargetRatingAnalyst
    Lantheus Holdings Inc.
    $LNTH
    2/26/2026Mkt Perform → Outperform
    William Blair
    Lantheus Holdings Inc.
    $LNTH
    12/12/2025$80.00Hold → Buy
    Truist
    Lantheus Holdings Inc.
    $LNTH
    10/8/2025$77.00Buy → Neutral
    Goldman
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    Lantheus Holdings Inc.
    $LNTH
    8/12/2025$63.00Buy → Hold
    Truist
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    Structure Therapeutics Inc.
    $GPCR
    5/2/2025$60.00Buy
    Citigroup
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings upgraded by William Blair

    William Blair upgraded Lantheus Holdings from Mkt Perform to Outperform

    2/26/26 12:20:43 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings upgraded by Truist with a new price target

    Truist upgraded Lantheus Holdings from Hold to Buy and set a new price target of $80.00

    12/12/25 8:36:54 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings downgraded by Goldman with a new price target

    Goldman downgraded Lantheus Holdings from Buy to Neutral and set a new price target of $77.00

    10/8/25 8:24:33 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    SEC Filings

    View All

    SEC Form S-8 filed by Structure Therapeutics Inc.

    S-8 - Structure Therapeutics Inc. (0001888886) (Filer)

    2/26/26 5:22:42 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Structure Therapeutics Inc.

    10-K - Structure Therapeutics Inc. (0001888886) (Filer)

    2/26/26 4:40:49 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Structure Therapeutics Inc. (0001888886) (Filer)

    2/26/26 4:11:24 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

    Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026  Aleniglipron Phase 3 initiation expected in 2H 2026 Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026 Cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, expected to provide cash runway through the end of 2028 SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Structure Th

    2/26/26 4:02:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growthCompany provides full year 2026 rev

    2/26/26 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Casper Joseph Michael

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/17/26 7:00:43 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Casper Joseph Michael

    3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/17/26 7:00:15 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

    WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company. "As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board," said Frank Watanabe, president and chi

    12/8/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BMRA
    $BWV
    Financials

    Live finance-specific insights

    View All

    Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growthCompany provides full year 2026 rev

    2/26/26 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    2/12/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care